Why the study?
Female patients with DMR can have worse mitral valve repair outcomes, motivating an evaluation of sex-specific differences in contemporary M-TEER.
Does contemporary mitral transcatheter edge-to-edge repair (M-TEER) result in comparable 1-year safety, survival, and echocardiographic effectiveness between female and male patients with prohibitive surgical risk and 3+/4+ degenerative mitral regurgitation?
Does contemporary mitral transcatheter edge-to-edge repair (M-TEER) result in comparable 1-year safety, survival, and echocardiographic effectiveness between female and male patients with prohibitive surgical risk and 3+/4+ degenerative mitral regurgitation?
In prohibitive surgical risk patients with degenerative mitral regurgitation from the CLASP IID trial, female patients achieved comparable 1-year survival, safety, echocardiographic MR reduction, and quality-of-life improvements to male patients following contemporary M-TEER, despite worse baseline functional status and smaller cardiac dimensions.
Answers are grounded in this paper and cite their sources.
Sex differences in M-TEER outcomes for DMR warrant caution in women; hypothesis-generating and leaves open need for sex-specific strategies.
Background Female patients with degenerative mitral regurgitation (DMR) can have worse mitral valve repair outcomes. We aim to study sex-specific differences in contemporary mitral transcatheter edge-to-edge repair (M-TEER). Methods One-year outcomes in prohibitive surgical risk patients with 3+/4+ DMR from the randomized CLASP IID trial were analyzed by sex. Results The analysis population comprised 34.7% female patients (n = 102) and 65.3% male patients (n = 192). Female patients had significantly lower body mass index, fewer comorbidities, and smaller left ventricular indexed volumes and mitral valve area at baseline. At 1 year, there were no significant differences between female and male patients in survival (92.1% vs 90.9%, P = .754), freedom from heart failure hospitalization (91.7% vs 94.4%, P = .366), and freedom from major adverse events (86.0% vs 85.9%, P = .985), respectively. Both sexes achieved a significant reduction in mitral regurgitation from baseline at 1 year ( P < .001), with comparable mitral regurgitation ≤1+ (75.6% vs 75.0%, P = 1.000). Baseline-adjusted changes in indexed left ventricular volumes (diastolic: –18.8 vs –15.7 mL, P = .087; systolic: –5.6 vs –5.0 mL, P = .645) and mitral gradients (+1.4 vs +1.1 mm Hg, P = .116) were similar, with no indication of stenosis. New York Heart Association class I/II was achieved in 86.4% of female patients vs 88.7% of male patients ( P = .674), and the Kansas City Cardiomyopathy Questionnaire overall score increased by 14.1 vs 15.8 points ( P = .502), respectively. Conclusions In the CLASP IID randomized trial, both sexes experienced high survival and freedom from major adverse events and heart failure hospitalization at 1 year post–M-TEER, with comparable improvements in echocardiographic, functional, and quality-of-life measures, despite differences in clinical presentation and the procedure. Results demonstrate that female patients achieve favorable safety and effectiveness outcomes, comparable to male patients, with contemporary M-TEER in DMR.
No takes yet. Share an insight, caveat, or question.
Szerlip et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: